Coronavirus Covid-19 Information

BLU-667-2303 AcceleRET

A Randomized, Open-Label, Phase 3 Study of Pralsetinib (formerly known as BLU-667) versus Standard of Care for First Line RET-fusion, Metastatic Non-Small Cell Lung Cancer.
Study Phase: Phase 3
Principal Investigator: Dr Sinead Cuffe
Further information

BMS CA 209-73L

A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer
Study Phase: Phase 3
Principal Investigator: Dr Sinead Cuffe
Further information

M14-239

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
Study Phase: Phase 2
Principal Investigator: Dr Sinead Cuffe
Further information

MK-3475-671 (KEYNOTE-671)

A Phase III, Randomized, Double-blind Trial of Platinum Doublet chemotherapy +/- Pembrolizumab as neo-adjuvant/adjuvant therapy for participants with resectable stage IIb or IIIa non-small cell lung cancer
Study Phase: Phase 3
Principal Investigator: Sinead Cuffe
Further information

Enquire about a Cancer Clinical Trial

If you would like more information on Cancer Clinical Trials you can contact us.

Make an enquiry